Drug therapy for pulmonary arterial hypertension

田丹,周达新,吕迁洲
DOI: https://doi.org/10.1378/chest.124.6.2045
2013-01-01
Abstract:Pulmonary arterial hypertension(PAH) is caused by heterogeneous diseases and different pathogenesis with the increase of pulmonary arterial pressure of the disease state for the manifestation.Traditional treatments mainly focus on supportive treatment and basic treatment such as non-selective vasodilators.Recent years,with the deep study of pathological mechanism,treatments of PAH turn from nonspecific treatment to pathogenesis specific therapy.Six drugs which were approved by FDA have already applied in clinical PAH treatment.They belong to prostacyclin analogues,endothelin receptor antagonists(ERA) and phosphodieste rase-5 inhibitors.5-HT receptor antagonists,Rho-kinase inhibitors and PAR-2 inhibitors are still at preclinical stage.
What problem does this paper attempt to address?